Accused of forging a seal, achieving a sales volume of 0.117 billion in two years. Jimin Health is suing its own vice president. Can Dealers get their payment back? | Quick read announcement.

① The stamp of Jimin Health is identified as "forged," and the investigation revealed the existence of a "supplementary agreement"; ② Jimin Health is at risk of being sued by Dealers, stating that "it will actively communicate with the involved Dealers to seek a proper solution"; ③ The industry believes that the involved vice president may have undertaken a considerable sales task, thus "taking a risk," while it's very difficult for suppliers to recover the payments in the short term.

cls.cnMar 26 11:33 ET

Shanghai Haohai Biological Technology 2024 Annual Report: The proportion of medical aesthetics business has further increased, and the impact of policies such as centralized procurement has not yet faded.

① The medical beauty Sector achieved revenue of 1.195 billion yuan, a year-on-year increase of 13.08%, with the business proportion rising from 39.96% to 44.38%, becoming the core driving force behind the company's current performance growth. ② Compared to the "counter-trend growth" of the medical beauty Sector, multiple sectors of Shanghai Haohai Biological Technology experienced varying degrees of revenue decline, and have not yet overcome the painful adjustment period of policies.

cls.cnMar 22 03:10 ET

Q4 performance declined year-on-year, Imeik Technology Development continues to increase investment in research and development | Interpretations

① In 2024, Imeik Technology Development's revenue and Net income growth rates both fell to single digits, and in Q4, there was even a decline in performance. ② The company continues to increase its investment in research and development, with products like injectable botulinum toxin type A entering the registration application stage.

cls.cnMar 19 11:03 ET

A large number of consultations! The benefits of childcare subsidies continue to be released, and Assisted Reproduction companies are looking forward to a "combination punch."

① Recently, policies favorable for child-rearing have emerged from both central and local governments, with some regions even offering substantial monetary incentives to encourage childbirth. ② Industry experts pointed out to reporters at Caijing that the introduction of child-rearing subsidy policies can, to some extent, reduce the burden and concerns for young couples regarding childbirth. ③ Insiders from Assisted Reproduction companies have expressed that measures such as promoting cultural awareness of male responsibility in child-rearing are also highly anticipated in the industry.

cls.cnMar 17 01:44 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

Is Imeik Technology Development's premium of 13 times for controlling the leading aesthetic medical brand in South Korea too high?| K Commentary

① Imeik Technology Development holds a 13 times premium stake in South Korea's REGEN Biotech, which possesses two core products, AestheFill and PowerFill; ② If Imeik Technology Development wants to reclaim exclusive agency rights for AestheFill in China from JiangSu WuZhong Pharmaceutical Development, certain costs will inevitably need to be incurred; ③ The competition in the medical beauty regeneration sector is intensifying, and recently two hydroxyapatite products have been approved.

cls.cnMar 13 07:57 ET